Business
Century Therapeutics to Present at the AACR Annual Meeting 2023
PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced
About this update from Century Therapeutics, Inc.
[{"type":"text","content":"PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that preclinical data from the Company’s iPSC-based cell therapy platform will be presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 17, 2023. Details of the poster presentation are as follows: Abstract Number: 2914Title: iPSC-derived CAR-NK cell therapy: nominating clinical candidate clones through integrated multi-functional analysisPoster Board Number: 19Session Title: Natural Killer and Natural Killer T Cell-based Cellular TherapiesSession Date: Monday, April 17, 2023Session Time: 1:30 – 5:00 PM ETPresenter: Michael Hall, PhD, Senior Scientist, Computational Immunology, Century Therapeutics Full abstracts are currently available through the AACR conference website. About Century TherapeuticsCentury Therapeutics, Inc. (NASDAQ: IPSC) is a clinical-stage biotechnology company harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit https://www.centurytx.com/. Century Therapeutics Forward-Looking StatementThis press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limi...